Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Indivior raises forecasts on Suboxone strength

Indivior Plc raised the company’s full-year 2019 forecasts as the embattled British drugmaker’s best-selling opioid addiction drug Suboxone fared better than expected in the face of competition from copycats.

Read More »

U.S. judge overseeing opioid litigation won’t be disqualified: U.S. appeals court

A federal appeals court rejected a bid by eight drug retailers and distributors to disqualify the judge overseeing nationwide opioid litigation after they claimed his rulings, public statements and efforts to encourage settlements created an appearance of bias.

Read More »

U.S. Supreme Court rejects Acorda appeal

The U.S. Supreme Court declined to hear Acorda Therapeutics Inc.’s appeal of a lower court ruling that allowed generic versions of the company’s multiple sclerosis treatment Ampyra.

Read More »

Favorable court ruling for Vectura and Sandoz vs. GSK

A British court ruled in favor of Vectura Group and the company’s partner Sandoz over the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

Read More »

Johnson & Johnson settles Ohio lawsuits to avoid federal trial

Johnson & Johnson will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation’s opioid epidemic.

Read More »

Drug companies urge appeals court to remove judge from U.S. opioid litigation

Eight drug companies urged a federal appeals court to disqualify the judge overseeing nationwide opioid litigation, in a last-ditch effort to avoid having him preside over a landmark trial.

Read More »

Opioid plaintiffs fight bid to disqualify U.S. judge before trial

Lawyers for cities and counties suing drug companies over the opioid epidemic objected to a bid by pharmaceutical distributors and pharmacies to disqualify the federal judge overseeing the cases, saying there is no basis and came too late.

Read More »

Purdue Pharma Files for Bankruptcy

Purdue Pharma filed for Chapter 11 bankruptcy and agreed to pay between $10 and $12 billion to settle the drug manufacturer’s involvement in the health-care crisis.

Read More »

Purdue Pharma reaches tentative opioid settlement with some: sources

OxyContin maker Purdue Pharma LP reached a tentative agreement with some plaintiffs to resolve litigation over the company’s alleged role in fueling the U.S. opioid crisis and plans to tussle with states opposing the settlement offer in bankruptcy proceedings, people familiar with the matter said.

Read More »

U.S. government gives states nearly $2 billion to combat opioid crisis

The U.S. Department of Health and Human Services will offer states more than $1.8 billion in new funding to fight the opioid epidemic.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom